Advancing Metabolic Disease Drug Development

Advancing metabolic disease therapies requires more than demonstrating efficacy. Translational relevance, drug metabolism, tolerability, and safety all help shape candidate selection and development decisions.
In this on-demand webinar, experts explore integrated preclinical strategies to support metabolic disease drug candidates from discovery through IND-enabling studies.
Watch to gain insights into:
• In vitro and in vivo studies for candidate evaluation and translational assessment
• DMPK and nonclinical safety strategies to support IND-enabling development
• Aligning preclinical study execution with key U.S. and European regulatory expectations
Related Content
Metabolic dysfunction-associated alcohol-related liver disease (MetALD) presents unique challenges for preclinical drug development, requiring models that capture the combined effects...
VIEW RESOURCEMetabolic dysfunction-associated steatohepatitis (MASH) remains a significant global health challenge, driven by a complex interplay of lipid dysregulation, inflammation, and...
VIEW RESOURCE
